Neutron-capture therapy of human cancer: In vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system (immunoreactivity/p-[1,2-dicarba-closo-[1-3H] 
More than 3 decades have passed since Bale suggested that boron conjugated to antitumor antibodies might provide a selective and effective method of cancer therapy because of the property of boron-10 nuclei to absorb thermal neutrons (1) . This reaction releases an a-particle and recoiling lithium-7 ion, which have limited penetration and, thereby, a restricted cytocidal range. Because tissues not containing boron-10 have low neutron-capture cross-section values for thermal neutrons (2), a selective tissue cytotoxicity can be achieved in tissues containing boron-10 that receive irradiation with thermal neutrons. Thus, it is desirable to achieve a high gradient between the boron-10 concentration in tumor as compared to adjacent normal tissues. Recent clinical studies have affirmed that a number of antitumor antibodies can accrete selectively in tumors containing the appropriate antigen target, and when these antibodies are labeled with a suitable radionuclide, tumor imaging (radioimmunodetection of cancer) is achieved (3) (4) (5) (6) (7) (8) (9) . Thus, it became apparent to us that the conditions were ripe for a reexamination of the potential use of antitumor antibodies as a vehicle for bringing boron-10 into tumors as neutron-capture agents.
In an earlier study, we coupled p-[1,2-dicarba-closo- [ (10) , and found that boron labeling did not destroy the immunoreactivity of the antibodies labeled with eight carborane cages or less (11) . It was the objective of the current study to assess the tumorlocalizing capabilities of such boron-conjugated antibodies against CEA.
MATERIALS AND METHODS
Antibody Purification. Goat anti-CEA antibody was purified by affinity chromatography as reported (12) . Normal goat IgG was purchased from Miles and used without further purification. Protein concentration was determined by the absorbance at 280 nm, A1"m = 14, or by the Bio-Rad protein assay. (12) has been described (11) . The nitration of the phenyl ring of 2-phenyl-1,2-dicarbacloso-[1-3H]dodecaborane(12) produces a 4% ortho, 26% meta, and 70o para isomer mixture with no dinitro derivatives being detected (13) . These isomers were isolated by medium-pressure liquid chromatography. A 2.5 x 100 cm glass column was dry-packed over 2 days with silica gel (Kieselgel 60, 0.063-0.200 mm, 70-230 mesh; Merck) and equilibrated with 1:4 (vol/vol) ethyl acetate/heptane. In a minimum volume of ethyl acetate, 1.0 g of the nitration reaction mixture was dissolved and applied onto the silica gel column. The column was eluted with 1:4 ethyl acetate/heptane at 4 ml/min; after 300 ml the para isomer followed by the meta and ortho isomers were isolated with little loss of products by collecting 2.5-ml fractions. The Sn/HCl reduction of each of these nitro isomers gave the corresponding amino derivatives in quantitative yields. Diazotization of 2- (p-aminophenyl) -1,2-dicarba-closo- [1-3H] dodecaborane (12) and determination of the concentration of the diazonium chloride solution were carried out as described by Hawthorne et al. (14) . Determination of the specific activity for the tritiated carborane derivative [3H]DBD was as described (11 Table 2 ) were calculated by the following formulae: % injected dose per gram of tissue = 100 (cpm per g of tissue/total cpm injected); tumor/nontumor ratio = cpm per g of tumor/cpm per g of nontumor tissue; localization ratio = (cpm of anti-CEA antibody per g of tisssue/cpm of normal IgG per g)/(cpm of antibody injected/cpm of normal IgG injected); localization index = localization ratio in tumor tissue/localization ratio in blood. 
RESULTS AND DISCUSSION
Because the in vivo distribution of [3H]DBD-anti-CEA conjugates could not be monitored by 3H activity due to the low specific activity of the conjugates, the [3H]DBD-IgG conjugates were radioiodinated. As shown in Table 1 , antibody activities as determined by the binding of either tritium or the iodine isotope to a CEA immunoadsorbent or Kynar donkey anti-goat IgG were similar, indicating that neither the [3H]DBD coupling nor the subsequent radioiodination of the conjugates influenced antibody activity. Table 2 shows representative tissue distribution data from one of two separate in vivo localization experiments comparing nonconjugated anti-CEA antibody to carborane-conjugated antibody (carborane:IgG ratio = 3). The data show that conjugation of carborane to the anti-CEA antibody did not appreciably alter the specific tumor localization properties of the antibody, nor was there any significant difference in the antibody distribution in the nontumor tissues (Fig. 1) . The conjugated and nonconjugated antibody as well as the normal IgG were all cleared from the circulation at the same rate (Fig. 2 Left) , but the average percentage of the conjugat- Table 2. ed antibody remaining in the circulation was generally observed to be slightly lower than that of the nonconjugated antibody. Maximum accretion of the antibody in the tumor was observed at day 3 for both samples (Fig. 2 Right) . The average percentage of the injected dose per g of tumor for the nonconjugated antibody was higher'than that for the conjugated antibody on day 3, but the difference was not statistically significant (P > 0.10). The tumor localization ratio for the conjugated antibody/normal IgG mixture on day 7 was significantly higher (P < 0.001) than that for the nonconjugated mixture. The difference in the localization ratios on day 7 was not attributed to the enhanced accretion of specific antibody in the tumor, since both the conjugated and non- conjugated anti-CEA antibody concentrations were the same (Fig. 2 Right). However, differences were evident in the amount of normal IgG in the blood and the tumor (Fig. 2) . Calculation of the localization index, a value that corrects for radioactivity differences in the blood (17) , revealed that there was no significant difference between the conjugated and nonconjugated samples (5.4 ± 0.48 and 4.9 ± 0.17, respectively). This suggests that the major factor contributing to the lower localization ratio of the nonconjugated sample was due to the slower clearance from the blood of the nonconjugated normal IgG. The plasma stability of the [3H]DBD-anti-CEA antibody was determined by affinity chromatography after incubation [3H]DBD-IgG (100 p.l) was incubated for 24 hr at 370C in 1 ml of 0.01 M P04-buffered saline, pH = 7.2 (untreated), or in 1 ml of normal hamster plasma. The samples were then passed over a CEA immunoadsorbent, and the amount of 3H activity was determined.
of the conjugated antibody in normal hamster plasma for 24 hr at 370C. The percentage of [3H]DBD-anti-CEA antibody bound to a CEA immunoadsorbent remained the same after incubation in plasma (Table 3) , indicating no loss in the amount of [3H]DBD from the coupled antibody.
From the foregoing results, it is apparent that the carborane-conjugated anti-CEA antibodies retained immunoreactivity as well as their efficacy for selective accretion in the CEA-containing human colonic tumors, thus supporting the view that boron-10 can be transported to neoplasms selectively by being conjugated to antitumor antibodies. Indeed, the localization ratios and tumor/nontumor ratios achieved with the boron-labeled antibodies were not inferior to those obtained with nonconjugated antibodies to CEA. Nevertheless, it is as yet premature to conclude that the quantity of boron delivered to the tumors is sufficient to achieve their destruction by neutron-capture therapy, despite the fact that up to 30 boron-10 atoms can be conjugated to each antibody
